Openbookopenbook
Equity
VTRLY
+0.0 · +0.00%
USD · PINK

Vitrolife AB (publ)(VTRLY) Stock Analysis | Healthcare

USD --+0.00%
Reward40Moderate
Risk72High
75%Data
Thin -146% profit margin · Revenue down 7% YoY
Structurally Challenged
Market Cap:1.29Bn
ⓘ
Reward Rating
40
Moderate
Reward Assessment
75% data coverage
Bottom 10% of stocksView factors
ⓘ
Risk Rating
72
High
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on VTRLY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for VTRLY, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Vitrolife AB (publ)?

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.

VTRLY · Verdict

Moderate reward · high risk

VTRLY's standout is balance sheet; volatility and growth weigh on the picture.

Based on 88% data coverage

VTRLY · Verdict

What’s working & what to watch

Strengths 1

  • Balance sheet85/100

    Interest covered 12.1×

Watchouts 4

  • Volatility5/100

    Weak vs peers

  • Growth31/100

    Revenue +2.1% CAGR

  • Profitability40/100

    -146% net margin · -47% ROE

  • Valuation45/100

    In line with peers

Model-based scoring. For information only — not financial advice.

What is Vitrolife AB (publ)?

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 1.29B.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (40)

The scoring profile indicates limited reward potential at this time, with momentum and size offering the most support. Risk indicators are high — this profile reflects meaningful downside exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Devices names that are close enough in size to make side-by-side comparison useful.

CSBTFSmall Cap / 1.3B market cap
Kuros Biosciences AG
Compare
IARTSmall Cap / 1.3B market cap
Integra LifeSciences Holdings
Compare
ELEAFSmall Cap / 1.3B market cap
EL.En. S.p.A
Compare
Company Information
SectorHealthcare
IndustryMedical Devices
Market Cap1.29B
P/E RatioN/A
Dividend YieldN/A
Beta2.057
Insider Activity
12M windowNo data
No insider activity data available for this ticker.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.